

Press Release September 15, 2017

Chaperone Therapeutics Awarded National Institutes of Health grant to develop therapeutics to slow the progression of Huntington's disease and other neurodegenerative disorders through restoration of protein folding mechanisms

Chaperone Therapeutics, Inc. is the recipient of a two-year Small Business Innovation Research Grant from the National Institute on Aging. This award supports the preclinical development of its proprietary lead molecules to deliver a clinical candidate as a disease-modifying therapy of Huntington's disease. Chaperone Therapeutics' approach takes advantage of a key cellular repair pathway affected in human disease brain and one that has been validated in genetically modified animals. The molecules in development are expected to attenuate the pathophysiological cascade initiated by misfolded proteins associated not only with Huntington's disease but also other neurodegenerative proteopathies such as Alzheimer's disease and Parkinson's disease.

"This award will accelerate the delivery of a breakthrough therapy to address the debilitating symptoms of several neurodegenerative disorders", says Kalpana Merchant, the President and CEO of Chaperone Therapeutics, Inc. "I am honored to be a part of a passionate team focused on translating innovative science into transformational medicines for patients".